Listing of Claims

Please cancel claims 20-22 without prejudice to subsequent renewal or future prosecution. This following listing of claims will replace all prior versions and listings of claims in the application.

1. (Previously presented) A method for treating a metabotropic glutamate disorder, comprising administering to a subject in need thereof, an effective amount of (a) a first antagonist which modulates metabotropic glutamate receptor 2 and/or metabotropic glutamate receptor 3, and (b) a second antagonist which modulates metabotropic glutamate receptor 5, thereby treating the disorder; wherein the metabotropic glutamate disorder is selected from the group consisting of depression, nicotine addiction, alcohol addiction, opiate addiction, amphetamine addiction, cocaine addiction, and methamphetamine addiction.

2. (Previously presented) A method for treating a metabotropic glutamate disorder, comprising administering to a subject in need thereof, an effective amount of (a) a first antagonist which modulates metabotropic glutamate receptor 2, and (b) a second antagonist which modulates metabotropic glutamate receptor 5, thereby treating the disorder; wherein the metabotropic glutamate disorder is selected from the group consisting of depression, nicotine addiction, alcohol addiction, opiate addiction, amphetamine addiction, cocaine addiction, and methamphetamine addiction.

3. (Previously presented) A method for treating a metabotropic glutamate disorder, comprising administering to a subject in need thereof an effective amount (a) a first antagonist which modulates metabotropic glutamate receptor 3 and (b) a second antagonist which modulates metabotropic glutamate receptor 5, thereby treating the disorder; wherein the metabotropic glutamate disorder is selected from the group consisting of depression, nicotine addiction, alcohol addiction, opiate addiction,

amphetamine addiction, cocaine addiction, and methamphetamine addiction.

4. (previously presented) The method of claim 1, wherein the disorder is an addictive disorder.

5. (original) The method of claim 4, wherein the addictive disorder is nicotine addiction, alcohol addiction, opiate addiction, amphetamine addiction, methamphetamine addiction, or cocaine addiction.

6. (original) The method of claim 4, wherein the addictive disorder is nicotine addiction.

7. (original) The method of claim 4, wherein the addictive disorder is cocaine addiction.

8. (previously presented) The method of claim 1, wherein the disorder is depression.

9. (Previously presented) The method according to claim 1, wherein the antagonist which modulates metabotropic glutamate receptor 5 is 2-methyl-6-(phenylethynyl)-pyridine, and the antagonist which modulates metabotropic glutamate receptor 2 and/or metabotropic glutamate receptor 3 is 2S-2-amino-2-(1S,2S-2-carboxycyclopropan-1-yl)-3-(xanth-9-yl)propionic acid .

10. (Withdrawn) A combination comprising (a) at least a first active ingredient selected from a metabotropic glutamate receptor 2 antagonist and a metabotropic glutamate receptor 3 antagonist, and (b) at least a second active ingredient being a metabotropic glutamate receptor 5 antagonist, in which the active ingredients are

present in each case in free form or in the form of a pharmaceutically acceptable salt, and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use.

11-13. (Canceled)

14. (withdrawn) The combination according to claim 10 which is a combined preparation or a pharmaceutical composition.

15. (withdrawn) The combination according to claim 10 for simultaneous, separate or sequential use in the treatment of an addictive disorder or depression.

16. (Previously presented) A method of treating a warm-blooded animal having an addictive disorder or depression comprising administering to the animal a combination according to claim 10 in a quantity which is jointly therapeutically effective against an addictive disorder or depression and in which the compounds can also be present in the form of their pharmaceutically acceptable salts; wherein the addictive disorder is selected from the group consisting of nicotine addiction, alcohol addiction, opiate addiction, amphetamine addiction, cocaine addiction, and methamphetamine addiction.

17. (withdrawn) A pharmaceutical composition comprising a quantity, which is jointly therapeutically effective against an addictive disorder or depression, of a pharmaceutical combination according to claim 10 and at least one pharmaceutically acceptable carrier.

18. (canceled)

19. (withdrawn) A commercial package comprising a combination according to claim 10 together with instructions for simultaneous, separate or sequential use thereof in the treatment of an addictive disorder or depression.

20-26. (Canceled)

27. (Previously presented) A method for treating an addictive disorder, comprising: a) administering to a subject in need thereof, an effective amount of a first antagonist that modulates mGluR5 during a first time period, wherein the first time period is a time period wherein the subject expects to be in an environment wherein, or exposed to stimuli in the presence of which, the subject habitually uses an addictive substance; and b) administering a second antagonist that modulates mGluR2 and/or 3 during a second time period, wherein the second time period is a time period wherein the subject is suffering from withdrawal and/or depression; wherein the addictive disorder is selected from the group consisting of nicotine addiction, alcohol addiction, opiate addiction, amphetamine addiction, cocaine addiction, and methamphetamine addiction.

28. (Previously presented) The method of claim 27, wherein the antagonist that modulates mGluR5 is 2-methyl-6-(phenylethynyl)-pyridine and the antagonist that modulates mGluR2 and/or 3 is 2S-2-amino-2-(1S,2S-2-carboxycyclopropan-1-yl)-3-(xanth-9-yl)propionic acid.

29. (Previously presented) A method for treating depressive symptoms and anxiety symptoms of depression, comprising administering to a subject in need thereof, an effective amount of (a) a first antagonist which modulates metabotropic glutamate receptor 2 and metabotropic glutamate receptor 3, and (b) a second antagonist which modulates metabotropic glutamate receptor 5, thereby treating the depressive

symptoms and anxiety symptoms of depression.

30. (Previously presented) The method of claim 29, wherein the antagonist of metabotropic glutamate receptor 2 and metabotropic glutamate receptor 3 is administered when the subject experiences depression symptoms, and the antagonist of metabotropic glutamate receptor 5 is administered when the subject experiences anxiety symptoms.

31. (Previously presented) The method of claim 30, wherein the antagonist of metabotropic glutamate receptor 2 and metabotropic glutamate receptor 3 is 2S-2-amino-2-(1S,2S-2-carboxycyclopropan-1-yl)-3-(xanth-9-yl)propionic acid, and the antagonist of metabotropic glutamate receptor 5 is 2-methyl-6-(phenylethynyl)-pyridine.

32. (Previously presented) The method of claim 1, wherein the first antagonist and the second antagonist are administered to the subject sequentially or simultaneously.

33. (Previously presented) The method of claim 29, wherein the first antagonist and the second antagonist are administered to the subject sequentially or simultaneously.